Skip to content

Study on the Role of Low-Density Lipoprotein Receptor in Pathological Classification and Disease Progression of Primary Aldosteronism

Study on the Role of Low-Density Lipoprotein Receptor in Pathological Classification and Disease Progression of Primary Aldosteronism

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600123146
Enrollment
Unknown
Registered
2026-04-22
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary aldosteronism

Interventions

Primary Aldosteronism Group (APA Group):None
Non-functional Adenoma Group:None

Sponsors

The Army Specialized Medical Center of the People's Liberation Army of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Positive initial screening with aldosterone-renin ratio (ARR): plasma aldosterone/renin activity ratio > 30 or plasma aldosterone/renin concentration ratio > 3.7, respectively. 2.At least one positive confirmatory test, including the saline infusion test, captopril challenge test, oral high-sodium diet test, or fludrocortisone suppression test. Patients with spontaneous hypokalemia, renin levels below the lower limit of detection, and plasma aldosterone concentration > 20 ng/dL were exempt from confirmatory testing. 3.Unilateral lesion was indicated by adrenal computed tomography (CT) or adrenal vein sampling (AVS). 4.Age ranged from 18 to 75 years.

Exclusion criteria

Exclusion criteria: 1.Incomplete detection results of renin and aldosterone in the initial screening test; 2.Medications used during screening interfered with the detection of renin and aldosterone, resulting in inaccurate test results; 3.Complicated with severe cardiac, hepatic or renal insufficiency; 4.Pregnant or lactating women; 5.Individuals with drug abuse, alcohol addiction, or uncontrollable psychiatric disorders; 6.Patients with intellectual disability or immature mental capacity who are unable to control their own behaviors; 7.Those who refuse to participate in the present study.

Design outcomes

Primary

MeasureTime frame
Lipid metabolism indicators;Serum and urinary aldosterone;Pathological classification;Results of computed tomography (CT) examination;Results of adrenal vein sampling;Electrolytes;

Countries

China

Contacts

Public ContactLu Zongshi

The Army Specialized Medical Center of the People's Liberation Army of China

741230863@qq.com+86 23 68757113

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026